Clicky

Orion Oyj A(ORNAV)

Description: Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.


Keywords: Drugs Chemical Compounds Active Pharmaceutical Ingredients Breast Cancer Prostate Cancer Parkinson's Disease Asthma Contract Manufacturing Services Chronic Obstructive Pulmonary Disease Self Care Phenols Cancer Therapeutics Copd Treatment Of Prostate Cancer Healthcare Centers Combination Drugs Fluticasone Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Formoterol Healthcare Service Providers Acute Decompensated Heart Failure Bispecific Antibody Cancer Human And Veterinary Pharmaceuticals Antisedan Budesonide Carbidopa/Levodopa/Entacapone Comtess Dexdor Fareston Fluticasone/Salmeterol Formamides Precedex Salmeterol Self Care Products Simdax Stalevo Tessie

Home Page: www.orion.fi

Orionintie 1A
Espoo, 02200
Finland
Phone: 358 10 4261


Officers

Name Title
Mr. Timo Lappalainen Advisor
Dr. Liisa Hurme Pres, CEO & Chairman of Exec. Management Board
Mr. Jari Karlson M.Sc., M.Sc. (Econ.) CFO, Sr. VP of Animal Health & Member of the Exec. Management Board
Mr. Olli Huotari Ll.M. Sr. VP of Corp. Functions, Gen. Counsel, Sec. & Member of Exec. Management Board
Ms. Satu Ahomäki M.Sc., M.Sc. (Econ.) Sr. VP of Commercial Operations & Member of the Exe. Mgmt. Board
Ms. Virve Laitinen M.Sc. (Tech.), MBA Sr. VP of Specialty Products & Member of Exec. Management Board
Prof. Outi Vaarala M.D., Ph.D. Sr. VP for R&D and Member of Exec. Management Board
Mr. Juhani Kankaanpaa Sr. VP of Global Operations & Member of Exec. Management Board
Mr. Tuukka Hirvonen M.Sc.(Soc.) Investor Relations & Financial Communications Officer
Ms. Terhi Ormio VP of Communications

Exchange: HE

Country: FI

Currency: Euro (€)

Forward PE: 26.0417
Trailing PE: 21.8474
Price-to-Book MRQ: 7.2424
Price-to-Sales TTM: 5.33
IPO Date:
Fiscal Year End: December
Full Time Employees: 3527
Back to stocks